secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001628280-24-032182
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance
----------------------------------------------------------------

- GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
- FY2024 guidance raised: GAAP EPS $3.30-$3.40, adjusted $4.61-$4.71; organic sales growth 9.5%-10.0%.
- Medical Devices organic growth 12.1%; FreeStyle Libre sales $1.6B (+20.4% organic).
- New product approvals: Esprit BTK (FDA), Lingo/Libre Rio (FDA), AVEIR dual-chamber (CE Mark).
- Quarterly dividend $0.55 payable Aug 15; 52nd consecutive year of dividend increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/0001628280-24-032182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828024032182/abt-20240718.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-032182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer